Author:
Falenski Katherine W,Thorpe Andrew J,Schlosburg Joel E,Cravatt Benjamin F,Abdullah Rehab A,Smith Tricia H,Selley Dana E,Lichtman Aron H,Sim-Selley Laura J
Publisher
Springer Science and Business Media LLC
Subject
Psychiatry and Mental health,Pharmacology
Reference46 articles.
1. Aceto MD, Scates SM, Razdan RK, Martin BR (1998). Anandamide, an endogenous cannabinoid, has a very low physical dependence potential. J Pharmacol Exp Ther 287: 598–605.
2. Bohn LM, Dykstra LA, Lefkowitz RJ, Caron MG, Barak LS (2004). Relative opioid efficacy is determined by the complements of the G protein-coupled receptor desensitization machinery. Mol Pharmacol 66: 106–112.
3. Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Vogt LJ, Sim-Selley LJ (1999). Chronic delta9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptor-activated G-proteins in brain. J Neurochem 73: 2447–2459.
4. Breivogel CS, Lambert JM, Gerfin S, Huffman JW, Razdan RK (2008). Sensitivity to delta9-tetrahydrocannabinol is selectively enhanced in beta-arrestin2 −/− mice. Behav Pharmacol 19: 298–307.
5. Breivogel CS, Scates SM, Beletskaya IO, Lowery OB, Aceto MD, Martin BR (2003). The effects of delta9-tetrahydrocannabinol physical dependence on brain cannabinoid receptors. Eur J Pharmacol 459: 139–150.
Cited by
68 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献